• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
An arrow incrementally going up stairs before pointing straight up Blue background
CRO

Canadian $5M clinical trial program cuts start-up to 45 days

The QuickStart program initiated by Clinical Trials Ontario is an accelerated study start-up pathway to speed up patient access to clinical trials.
Marissa Russo Sep 29, 2026 3:04pm
New approach methodologies in safety and toxicology testing Why proving repeatability is the next hurdle for widespread adop

Why proving repeatability is the next hurdle for widespread adoption

Brought to you by Agilent Technologies
a lot of scissors

Enanta sheds staffers as key readouts loom

Sep 29, 2026 1:30pm
x

Fierce Biotech Layoff Tracker 2026: Enanta, BMS & more

Sep 29, 2026 1:30pm
un1Qure Genezen

uniQure stock crashes as Huntington’s gene therapy data weaken

Sep 29, 2026 9:28am
apoptosis cell death cancer cell death

ai3Bio buzzing with $48M for STING pathway targeting pipeline

Sep 29, 2026 9:00am
More News

Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug

Sep 29, 2026 3:50am

AstraZeneca scales Summit’s PD-1xVEGF combos with $2B investment

Sep 29, 2026 3:07am

Roche drops obesity antibody after flunked interim analysis

Sep 28, 2026 11:03am

Mirum posts ph. 3 hepatitis win for challenger to Gilead, Vir

Sep 28, 2026 9:36am
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings